Project Grant R61HL183015
Award Date 9/1/26
Completion Date 5/31/28
Dollars Obligated $638K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Houston, TX 77005, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded Baylor College of Medicine $701,116 under the Cardiovascular Diseases Research program (CFDA 93.837) on September 1, 2026, to investigate transcriptional mutagenesis as a novel mechanism driving heart failure. The research examines how oxidative stress promotes formation of 8-oxo-deoxyguanosine lesions in DNA, which disrupts transcriptional fidelity in cardiomyocytes. Aim 1 integrates long-read single-nucleus RNA sequencing from human heart...
- The National Heart, Lung, and Blood Institute awarded the University of Cincinnati Sponsored Research Services Division $1.57 million on July 6, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct research on targeted rewiring of fibrosis drivers to enhance cardiac reprogramming following myocardial infarction. The research addresses excessive cardiac fibrosis resulting from the heart's repair response, which can lead to adverse remodeling and heart failure. The...
- The federal Project Grant award, titled "ENHANCEMENT OF GENOME EDITING IN HEMATOPOIETIC STEM CELLS BY NUCLEIC ACIDS NANOPARTICLES DELIVERY OF CRISPR/CAS SYSTEM", was granted by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The $486,291 award, effective February 1, 2025 through January 31, 2028, supports the development of a nucleic acid nanoparticle technology to efficiently deliver the CRISPR/Cas9 system into...
- The National Heart, Lung, and Blood Institute awarded the Regents of the University of Michigan $167,400 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop nanoparticle-mediated delivery of CRISPR-Cas9 gene editing for sickle cell disease treatment. The project focuses on advancing non-viral platforms for therapeutic gene editing of hematopoietic stem and progenitor cells. Current gene therapy approaches using ex vivo viral transduction or...
- The National Heart, Lung, and Blood Institute awarded Baylor College of Medicine $625,035 on August 17, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to support research into the molecular mechanisms of mitochondrial calcium exchange in the heart. The research addresses mitochondrial calcium overload, which triggers cell death and tissue damage during ischemia-reperfusion injury—a secondary phase of cardiac damage that can account for up to 50 percent of final infarct...
- The National Institutes of Health National Heart Lung and Blood Institute awarded The Methodist Hospital Research Institute $789,693 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837, R01HL172902) to investigate alternative polyadenylation regulation in cardiac fibrosis. The research examines how depletion of the alternative polyadenylation regulator NUDT21 drives three-prime untranslated region shortening of profibrotic transcripts and contributes to...
- The National Institutes of Health National Heart Lung and Blood Institute awarded The University of Texas Health Science Center at San Antonio $118,125 on August 19, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to integrate long-read and short-read RNA sequencing data to identify and characterize alternative splicing events in healthy and diseased hearts. The recipient will reconstruct heart disease-specific transcriptomes using long-read RNA sequencing data from...
- The National Heart, Lung, and Blood Institute awarded Baylor College of Medicine $158,892 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to examine the impact of DNMT3A protein reduction on normal and clonal hematopoiesis. The research investigates mechanisms by which somatic DNMT3A mutations drive clonal hematopoiesis—the clonal expansion of mutated hematopoietic stem and progenitor cells—which accelerates with age and increases the risk of hematologic...
- The National Heart Lung and Blood Institute awarded Brigham & Women's Hospital $1.702 million on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a small activating RNA (saRNA) therapeutic approach for treating atherosclerotic cardiovascular disease in patients with metabolic dysfunction-associated steatohepatitis (MASH). The project restores macrophage efferocytosis—the clearance of dead cells—by reactivating the TIM4 receptor on macrophages using...
- The National Heart, Lung, and Blood Institute awarded the University of Virginia $776,745 on August 17, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to define and target DELE1-mediated mitochondrial stress signaling in cardiomyopathy. The research addresses how mitochondrial dysfunction drives cardiovascular disease, including heart failure and ischemic injury, by characterizing the molecular mechanisms through which DELE1 acts as a mitochondrial stress sensor to...